Leishmanicidal activity in vivo of a miltefosine derivative in Mesocricetus auratus
| dc.creator | Joana C. da Silva | |
| dc.creator | Juliana Barbosa Nunes | |
| dc.creator | Vanessa Silva Gontijo | |
| dc.creator | Vanessa Silva Gontijo | |
| dc.creator | Rossimiriam Pereira de Freitas | |
| dc.creator | Rosemeire Brondi Alves | |
| dc.creator | Fábio Antônio Colombo | |
| dc.creator | Marcia Dalastra Laurenti | |
| dc.creator | Marcos José Marques | |
| dc.date.accessioned | 2024-08-05T14:48:09Z | |
| dc.date.accessioned | 2025-09-08T22:56:54Z | |
| dc.date.available | 2024-08-05T14:48:09Z | |
| dc.date.issued | 2020 | |
| dc.description.sponsorship | CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico | |
| dc.description.sponsorship | FAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais | |
| dc.description.sponsorship | CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | |
| dc.description.sponsorship | INCT – Instituto nacional de ciência e tecnologia (Antigo Instituto do Milênio) | |
| dc.format.mimetype | ||
| dc.identifier.doi | https://doi.org/10.1016/j.actatropica.2020.105539 | |
| dc.identifier.issn | 1873-6254 | |
| dc.identifier.uri | https://hdl.handle.net/1843/72580 | |
| dc.language | eng | |
| dc.publisher | Universidade Federal de Minas Gerais | |
| dc.relation.ispartof | Acta Tropica | |
| dc.rights | Acesso Aberto | |
| dc.subject | Química farmacêutica | |
| dc.subject | Leishmaniose visceral | |
| dc.subject | Resposta imune | |
| dc.subject.other | Miltefosine derivative | |
| dc.subject.other | Experimental treatment | |
| dc.subject.other | Visceral leishmaniasis | |
| dc.subject.other | Immune response | |
| dc.title | Leishmanicidal activity in vivo of a miltefosine derivative in Mesocricetus auratus | |
| dc.type | Artigo de periódico | |
| local.citation.volume | 209 | |
| local.description.resumo | Visceral leishmaniasis (VL) is a chronic and systemic disease; if untreated, it can cause death in a large number of cases. The therapy is based on the use of antimonials, which have been used for over 50 years. However, cases of resistance have been reported in some countries. In this context, miltefosine (MIL) was introduced to treat antimonial unresponsive cases. Nonetheless, in recent years MIL unresponsive and relapse cases of VL have increasingly been reported. In the current study, the therapeutic potential of compound 5-(4-(3-methanesulfonatepropyl)-1H-1,2,3-triazol-1-yl)dodecyl methanesulfonate (C11), an MIL derivative, was assessed in an experimental VL hamster model. For this purpose, golden hamsters (Mesocricetus auratus) were infected with Leishmania (L.) infantum chagasi and treated daily for 10 days with C11 and MIL administered orally; in addition, Glucantime (GLU), peritoneal route, were administered at 15, 10, 50 mg/kg body weight/day, respectively. Twenty four hours after the end of treatment the animals were euthanatized; and the specimens were collected to evaluate the relative mRNA expression of cytokines IFN-γ, TNF-α, IL-17, TGF-β, IL-4 and IL-10 in fragments of the spleen and liver; moreover, the parasitism in these organs was evaluated as well as the main histopathological alterations. The C11-treated animals showed greater expression of IL-17 and TNF-α cytokines and reduced expression of IL-10 in the spleen in comparison to the infected untreated group (UTG) (p <0.05). The C11 and GLU groups showed a significant reduction in the IgG levels in comparison to the UTG group (p <0.05). Moreover, the C11-treated animals had fewer parasites in the spleen than the UTG animals (reduction of 95.9%), as well as a greater preservation of white pulp architecture in the spleen than the UTG, GLU and MIL groups (p <0.05). For the liver, the animals from the C11 and MIL groups showed a significant increase in TNF-α relative expression in comparison to the UTG animals, which would explain the increase in the number of granulomas and the reduction in the parasitic load (p <0.05). Combined, these findings indicate that C11 is an interesting compound that should be considered for the development of new drugs against VL, mainly due to its leishmanicidal effect and immunostimulating action. | |
| local.identifier.orcid | https://orcid.org/0000-0003-2628-0357 | |
| local.identifier.orcid | https://orcid.org/0000-0003-1674-818X | |
| local.identifier.orcid | https://orcid.org/0000-0002-4920-072X | |
| local.identifier.orcid | https://orcid.org/0000-0001-6974-3724 | |
| local.identifier.orcid | https://orcid.org/0000-0003-0546-2549 | |
| local.identifier.orcid | https://orcid.org/0000-0002-1596-9709 | |
| local.identifier.orcid | https://orcid.org/0000-0002-1080-2440 | |
| local.identifier.orcid | https://orcid.org/0000-0003-3459-3169 | |
| local.publisher.country | Brasil | |
| local.publisher.department | ICX - DEPARTAMENTO DE QUÍMICA | |
| local.publisher.initials | UFMG | |
| local.url.externa | https://www.sciencedirect.com/science/article/pii/S0001706X19314895 |